|
|
|
|
Document Preview CuraGen and Abgenix Announce Progress in Antibody Alliance and Sign New Agreement for Antibody Production |
||||
|
|
||||
|
Click "Add to Cart" button to purchase document. |
||||
|
|
||||
|
Title: |
CuraGen and Abgenix Announce Progress in Antibody Alliance and Sign New Agreement for Antibody Production |
|||
|
Entities: |
||||
|
Date: |
2003 |
|||
|
Size: |
Preview shows 2KB of 10KB total |
|||
|
Price: |
$37 |
|||
|
ID: |
#288529 |
|||
|
|
||||
|
||||
|
|
||||
|
Start of Preview |
||||
[CURAGEN LOGO APPEARS HERE] [ABGENIX LOGO APPEARS HERE]
------------ ------------------------------------- -----------------------------
Contacts: Abgenix: CuraGen Corporation:
--------
Ami Knoefler Mark R. Vincent
1-510-284-6350 1-888-GENOMICS
www.abgenix.com www.curagen.com
------------ ------------------------------------- -----------------------------
FOR IMMEDIATE RELEASE
---------------------
CuraGen and Abgenix Announce Progress in Antibody Alliance and Sign New
Agreement for Antibody Production
- CuraGen Selects Fully-Human Monoclonal Antibody CR002 as a
Candidate for Treating Kidney Disease -
- Abgenix to Manufacture CR002 in its New Antibody Production Facility -
New Haven, CT and Fremont, CA - January 9, 2003 - CuraGen Corporation (NASDAQ:
CRGN), a genomics-based pharmaceutical company, and Abgenix, Inc. (NASDAQ:
ABGX), a biopharmaceutical company focused on antibody therapeutics, today
announced new developments in their ongoing antibody discovery and development
alliance. CuraGen and Abgenix scientists have successfully developed a fully
human monoclonal antibody (CR002) that is being investigated as a treatment for
IgA nephropathy, a form of glomerulonephritis (kidney inflammation) that may
lead to renal failure and the need for dialysis treatments. CuraGen has selected
this antibody drug candidate for development and has the right to develop this
candidate across all disease areas. In addition, CuraGen is further exploring
the utility of this antibody as a treatment for other forms of
glomerulonephritis, including nephritis associated with systemic lupus
erythematosus (SLE) and diabetic nephropathy.
As part of an expansion of the Abgenix and CuraGen antibody drug discovery and
development alliance, Abgenix and CuraGen have signed a new agreement under
which Abgenix will manufacture CuraGen's CR002 antibody in Abgenix's recently
|
End of Preview |
Home Intelligence Services Subscriptions News About Us